Sesen Bio, Inc.

NasdaqCM:SESN 주식 리포트

시가총액: US$2.6b

This company is no longer active

The company may no longer be operating, as it may be out of business. Find out why through their latest events.

Sesen Bio 향후 성장

Future 기준 점검 0/6

핵심 정보

19.3%

이익 성장률

4.38%

EPS 성장률

Biotechs 이익 성장25.4%
매출 성장률-85.7%
향후 자기자본이익률n/a
애널리스트 커버리지

Low

마지막 업데이트28 Feb 2023

최근 향후 성장 업데이트

분석 기사 • Aug 12

Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00

Investors in Sesen Bio, Inc. ( NASDAQ:SESN ) had a good week, as its shares rose 4.7% to close at US$4.04 following the...

Recent updates

Seeking Alpha • Sep 21

Sesen Bio and Carisma Therapeutics announce merger agreement

Sesen Bio (NASDAQ:SESN) and Carisma Therapeutics has entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes engineered macrophages and monocytes to potentially transform the treatment of cancer and other serious disorders. The combined company expected to have ~$180M of cash, equivalents and marketable securities at close, including $30M from a concurrent financing by Carisma, which is expected to fund the combined company through 2024. Also, the cash runway of combined company expected to enable multiple clinical readouts across Carisma programs. The combined company is expected to operate under the name Carisma Therapeutics and trade on Nasdaq under the ticker symbol “CARM”.
Seeking Alpha • Aug 08

Sesen Bio GAAP EPS of -$0.16 misses by $0.03

Sesen Bio press release (NASDAQ:SESN): Q2 GAAP EPS of -$0.16 misses by $0.03. Company continues to assess potential strategic alternatives with the goal of maximizing shareholder value. Cash, cash equivalents and marketable securities were $161.2 million as of June 30, 2022, compared to $151.1 million as of June 30, 2021. Shares -1.82% PM.
Seeking Alpha • Jul 27

Sesen Bio granted additional time period for regaining compliance

Nasdaq Listing Qualifications department notified Sesen Bio (NASDAQ:SESN) that it has been granted a second 180-day grace period, or until Jan.23, 2023 for regaining compliance with the minimum bid price requirement. In January, the company had received its non-compliance letter and was granted time until July 25, 2022, to regain compliance with the minimum bid price requirement. The stock will be transferred to the Nasdaq Capital Market effective July 28, 2022 and will continue to trade under the current symbol. Shares trading 2% down premarket
Seeking Alpha • Jul 18

Sesen Bio slips after decision to pause U.S. studies for lead asset

The shares of cancer-focused biotech Sesen Bio (NASDAQ:SESN) traded lower in the pre-market Monday after the company announced its decision to pause further development of its lead asset Vicineum in the U.S. Sesen (SESN) noted that after discussions with the FDA, the company reassessed the development path for Vicineum, including a Phase 3 trial for the treatment in non-muscle invasive bladder cancer (NMIBC). The decision to pause further studies allows the company to save cash as it explores potential strategic alternatives to maximize shareholder value, according to the management. Additionally, Sesen (SESN) expects to form a partnership for the further development of Vicineum. However, the company’s Chief Executive, Dr. Thomas Cannell, noted that the current commercial environment of NMIBC also led to its decision. “We have also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage,” he said. In Aug. 2021, the FDA declined to approve Vicineum for the treatment of BCG-unresponsive NMIBC.
Seeking Alpha • Jun 02

Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives

SESN is a clinical-stage biopharma company working on the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). FDA declined to approve the company's flagship drug Vicineum. Subsequently, management has started a strategic review. SESN trades at $0.58/share vs $0.75/share of net cash.
분석 기사 • Apr 17

We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
분석 기사 • Dec 05

We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Nov 24

Sesen Bio: Interesting Price Drop After CRL

Sesen received a CRL in August. Another trial will be needed. Sesen held a Type A meeting with the FDA on Oct. 29 on the CMC questions.
Seeking Alpha • Nov 17

Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022

The US FDA published the warning letter on October 27, 2021, just 2 days before CMC Type A meeting with Sesen Bio. The move informed its rejection of the BLA. Ahead of the Type A meeting, the burden of proof will be on Sesen’s side to show the efficacy of Vicineum post-2017. Sesen Bio is gearing towards product commercialization with strategic hires into 2022. Study shows that high-prescribing urologists would use a treatment agent branded with Vicineum in more than 80% of the BCG-unresponsive NMIBC patients as opposed to 17% with Keytruda. Sesen Bio is able to fund its capital operations including R&D until 2023 when it is expected to begin commercialization of Vicineum.
Seeking Alpha • Aug 23

Sesen Bio: The Road Ahead

The current FDA environment is under heavy scrutiny with much uncertainty. Sesen Bio's lead drug, Vicineum, received a complete response letter from the Agency which put tremendous pressure on the stock. The company is eager to conduct a Type A meeting with the FDA to discuss the path ahead.
분석 기사 • Aug 12

Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00

Investors in Sesen Bio, Inc. ( NASDAQ:SESN ) had a good week, as its shares rose 4.7% to close at US$4.04 following the...
분석 기사 • Feb 18

News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat

Today is shaping up negative for Sesen Bio, Inc. ( NASDAQ:SESN ) shareholders, with the analysts delivering a...
분석 기사 • Jan 26

Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. Indeed, Sesen Bio...
분석 기사 • Dec 21

Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook

With the business potentially at an important milestone, we thought we'd take a closer look at Sesen Bio, Inc.'s...

이익 및 매출 성장 예측

NasdaqCM:SESN - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/2025N/A-9-18N/A1
12/31/2024N/A-8-8N/A1
12/31/2023N/A-26-20N/A1
12/31/202240-202525N/A
9/30/202260-31010N/A
6/30/20222048-29-29N/A
3/31/20222254-43-43N/A
12/31/2021270-69-69N/A
9/30/20217-24-65-65N/A
6/30/202118-118-54-54N/A
3/31/202116-119-40-40N/A
12/31/202011-23-31-31N/A
9/30/202011-41-36-36N/A
6/30/2020N/A-32-39-39N/A
3/31/2020N/A-60-39-38N/A
12/31/2019N/A-107-38-38N/A
9/30/2019N/A-81-32-31N/A
6/30/2019N/A-82-30-30N/A
3/31/2019N/A-36-26-26N/A
12/31/2018N/A-34-23-23N/A
9/30/2018N/A-33-19-19N/A
6/30/2018N/A-29-18-18N/A
3/31/2018N/A-27-17-17N/A
12/31/20170-29-18-18N/A
9/30/20171-26-20-20N/A
6/30/201730366N/A
3/31/201730366N/A
12/31/201630233N/A
9/30/201630-5N/A-1N/A
6/30/20161-34N/A-31N/A
3/31/20161-35N/A-35N/A

애널리스트 향후 성장 전망

수입 대 저축률: SESN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: SESN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: SESN 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: SESN 은(는) 내년에 수익이 없을 것으로 예상됩니다.

고성장 매출: SESN 은(는) 내년에 수익이 없을 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: SESN의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2023/03/08 23:33
종가2023/03/07 00:00
수익2022/12/31
연간 수익2022/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Sesen Bio, Inc.는 7명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
John NewmanCanaccord Genuity
Swayampakula RamakanthH.C. Wainwright & Co.
Christopher HowertonJefferies LLC